MK-217
Executive Summary
MK-217: Newest member of the research compounds publicly discussed by Merck is an in-licensed product from Istituto Gentili (Italy) for reducing the symptoms of high blood calcium in metastic cancer patients. Merck is beginning a U.S. development program. The company describes the product generically as an inhibitor of bone destruction.
MK-217: Newest member of the research compounds publicly discussed
by Merck is an in-licensed product from Istituto Gentili (Italy)
for reducing the symptoms of high blood calcium in metastic cancer
patients. Merck is beginning a U.S. development program. The
company describes the product generically as an inhibitor of bone
destruction. |